ArticleNPJ precision oncology2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Steven W Criscione et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this papercites it